AOD-9604 research guide

AOD-9604 in Caruray — Fat Loss Peptide Research Guide

AOD-9604 research guide for Caruray. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.

Skip to Sourcing Guide Order AOD-9604 →

Finding AOD-9604 in Caruray

For anyone in Caruray searching for AOD-9604, the first thing to know is that this compound is distributed via specialist online vendors. This matters because AOD-9604 quality differs enormously across the market — from verified research-grade material to material with significant impurity issues — and the vendor is the entire quality system. Vendors worth sourcing from proactively publish batch-matched Certificates of Analysis containing HPLC purity data, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. This guide gives Caruray researchers the methodology to assess vendor quality rigorously and source verified-quality AOD-9604 with confidence.

AOD-9604 Mechanisms Explained

CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Caruray comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.

How to Evaluate AOD-9604 Vendors

The most effective path to quality AOD-9604 is starting with community forums — peptide forums aggregate real purchasing experience that are more reliable than search results. Mass spectrometry in the COA confirms that the main HPLC peak is actually AOD-9604 and not another compound with similar chromatographic behaviour — HPLC purity alone cannot verify molecular identity. For Caruray researchers evaluating new suppliers: a modest first purchase to test the product before scaling up your order is what experienced peptide researchers consistently do. For Caruray researchers making a first AOD-9604 purchase: work through this evaluation framework first, start with a modest quantity, and check that batch numbers on your vial match the COA before use.

Order AOD-9604 — ships to Caruray
COA-verified · International tracking · Research grade
Order Now →

AOD-9604 Research Safety Guide

As a research compound, AOD-9604 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and limited human studies. Reconstitute AOD-9604 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — equivalent to 25mcg per unit on an insulin syringe. Bacterial endotoxin contamination is the primary safety concern unique to this class of compound — verify endotoxin testing is documented in your batch COA before any injectable research application. Protocol documentation — keeping clear records of compound, timing, and method — is a fundamental research principle that makes anomalous results interpretable.

Frequently Asked Questions

What is the clinical trial history of AOD-9604?

AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.

How does AOD-9604 differ from growth hormone?

AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.

Order AOD-9604 today
COA-verified · International shipping available
Order Now →